New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitisb and d...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
Patients taking methotrexate for psoriasis or psoriatic arthritis were at a higher risk of developing liver disease than were patients with rheumatoid arthritis on methotrexate.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Treatment Persistence of Biologics in Psoriatic Arthritis Treatment Persistence of Biologics in Psoriatic Arthritis
A better understanding of biologic treatment persistence in psoriatic arthritis patients could help guide treatment decisions.Arthritis Research & Therapy (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 25, 2021 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world as the largest broad-...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cardiorespiratory Fitness Linked to Psoriasis, Psoriatic Arthritis
FRIDAY, Jan. 15, 2021 -- Low cardiovascular fitness in late adolescence is associated with an increased risk for incident psoriasis and psoriatic arthritis among men, according to a study published online Jan. 11 in PLOS ONE. Marta Laskowski, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Osteoporosis Prevalence in PsA Similar to General Population Osteoporosis Prevalence in PsA Similar to General Population
Previous research suggested a possible link between psoriatic arthritis and osteoporosis or osteopenia. However, no cohort studies appear to have examined this association.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 7, 2021 Category: Primary Care Tags: Rheumatology News Source Type: news

Skin Gene Expression May Explain PsA Treatment Responses Skin Gene Expression May Explain PsA Treatment Responses
Differences in gene expression between the skin and synovial tissues of people with psoriatic arthritis could explain why treatments targeting proinflammatory mechanisms don ' t improve joint symptoms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 15, 2020 Category: Internal Medicine Tags: Rheumatology News Source Type: news

CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoi... Biopharmaceuticals, Regulatory AbbVie, RINVOQ, upadacitinib, psoriatic arthritis, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

ACR Convergence: Psoriatic Arthritis ACR Convergence: Psoriatic Arthritis
Dr Saakshi Khattri reviews key abstracts about psoriatic arthritis from the annual ACR meeting, including a tool for early detection and a study showing dactylitis may signal an aggressive phenotype.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Increased falls risk in people with psoriatic arthritis-related foot problems: a novel finding - Carter K, Walmsley S, Oliffe M, Hassett G, Turner ADE.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - November 23, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3 Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
The oral JAK inhibitor was significantly more effective than placebo at primary and secondary endpoints. Safety risks were comparable to those seen in the treatment of rheumatoid and psoriatic arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Ixekizumab Treatment of Biologic-Naive Psoriatic Arthritis Ixekizumab Treatment of Biologic-Naive Psoriatic Arthritis
Is ixekizumab a safe and effective therapeutic option for psoriatic arthritis patients naive to biologic treatment?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 pandemic. Our wo...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Experts Assess Infection Risks for Patients on Biologics Experts Assess Infection Risks for Patients on Biologics
A group of experts have summarized and made recommendations about recent findings regarding infections that can occur during treatment for rheumatoid arthritis and psoriatic arthritis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 8, 2020 Category: Infectious Diseases Tags: Rheumatology News Source Type: news